Furthermore, it is not certain whether our dosage was appropriate for inhibiting JAK2 in HL and PMBCL tumor cells because we used the dosage recommended for myeloproliferative neoplasms. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.